Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

(2022) Yuto Unoh et al.   JOURNAL OF MEDICINAL CHEMISTRY

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron

(2022) Bao-Xue Quan et al.   Nature Microbiology

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

(2022) Aekkachai Tuekprakhon et al.   CELL

X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation

(2022) Jaeyong Lee et al.   Nature Communications

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir

(2022) Sho Iketani et al.   NATURE

Close relatives of MERS-CoV in bats use ACE2 as their functional receptors

(2022) Qing Xiong et al.   NATURE

SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model

(2021) Jingxin Qiao et al.   SCIENCE

The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities

(2021) Marco Robello et al.   JOURNAL OF MEDICINAL CHEMISTRY

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

(2021) Jamie Lopez Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

(2021) Dafydd R. Owen et al.   SCIENCE

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

(2020) Roujian Lu et al.   LANCET

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

(2020)   Nature Microbiology

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

(2020) Zhenming Jin et al.   NATURE

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

(2020) Wenhao Dai et al.   SCIENCE

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

(2020) Linlin Zhang et al.   SCIENCE

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

(2020) Chunlong Ma et al.   CELL RESEARCH

hERG toxicity assessment: Useful guidelines for drug design

(2020) Amanda Garrido et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Remdesivir: First Approval

(2020) Yvette N. Lamb   DRUGS

Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19

(2020) Robert L. Hoffman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Telaprevir: Changing the standard of care of chronic hepatitis C

(2013) AK Rajani et al.   Journal of Postgraduate Medicine

Screening technologies for ion channel drug discovery

(2010) Georg C Terstappen et al.   Future Medicinal Chemistry

Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor

(2010) Ashok Arasappan et al.   ACS Medicinal Chemistry Letters

Discovery and Structure−Activity Relationship of P1−P3Ketoamide Derived Macrocyclic Inhibitors of Hepatitis C Virus NS3 Protease

(2008) Srikanth Venkatraman et al.   JOURNAL OF MEDICINAL CHEMISTRY